Clinical Trials Browser

Phase 2/3 × Lung Neoplasms × Gastrointestinal × Clear all

Urinary Bladder Neoplasms, Gallbladder Neoplasms, Lung Neoplasms, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Salivary Gland Neoplasms, Skin Neoplasms, Colorectal Neoplasms, Hematologic Neoplasms

NCT06478108 2024-06-27

Interventional Software for Multi-immunotherapy of Solid Tumors

Phase 2/3 Recruiting

60 enrolled

GastrointestinalThoracic

Liver Neoplasms, Lung Neoplasms

NCT01902823 2019-12-13

Effect of Cancer Nurse Navigators on Patient Outcomes

Phase 2/3 Terminated

16 enrolled

BreastGastrointestinalGenitourinaryThoracic

Breast Neoplasms, Lung Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms

NCT01446874 2018-11-08

POPP

Phase 2/3 Terminated

150 enrolled 11 charts

GastrointestinalThoracic

Esophageal Neoplasms, Lung Neoplasms

NCT00123760 2016-02-25

Study of 18F-Fluorodeoxyglucose (FluGlucoScan) in Patients With Cancer or Suspected Cancer

Phase 2/3 Completed

10,838 enrolled

CNSGastrointestinalHead & NeckLymphoidThoracic

Brain Neoplasms, Lung Neoplasms, Lymphoma, Thyroid Neoplasms, Colorectal Neoplasms

NCT00332280 2013-03-20

Study to Evaluate the Clinical Benefit Response in Cancer Patients With Advanced Disease With AMT2003 Versus Placebo

Phase 2/3 Terminated

67 enrolled

GastrointestinalGenitourinaryThoracic

Colonic Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Gastrointestinal Neoplasms, Genital Neoplasms, Female, Liver Neoplasms, Lung Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Stomach Neoplasms

NCT00002930 2013-01-18

PET Scan in Patients With Lung and Esophageal Cancers That May Be Removed by Surgery

Phase 2/3 Completed

75 enrolled

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Lung Neoplasms

Clinical Trials

DETERMINE

Interventional Software for Multi-immunotherapy of Solid Tumors

Effect of Cancer Nurse Navigators on Patient Outcomes

POPP

Study of 18F-Fluorodeoxyglucose (FluGlucoScan) in Patients With Cancer or Suspected Cancer

Study to Evaluate the Clinical Benefit Response in Cancer Patients With Advanced Disease With AMT2003 Versus Placebo

PET Scan in Patients With Lung and Esophageal Cancers That May Be Removed by Surgery